Lumateperone: A Novel Antipsychotic for Schizophrenia.

OBJECTIVE

To provide a concise review of the new Food and Drug Administration (FDA)-approved antipsychotic, lumateperone, for use in schizophrenia.

DATA SOURCES

A literature search of PubMed was performed (January 2000 to May 2020) using the following key terms: , and . Abstracts from conferences, review articles, clinical trials, and drug monographs were reviewed.

STUDY SELECTION AND DATA EXTRACTION

Relevant English-language monographs and studies conducted in humans were considered.

DATA SYNTHESIS

Lumateperone was FDA approved for the treatment of schizophrenia in December 2019 based on 2 published randomized, double-blind, placebo-controlled trials. Lumateperone's pharmacology is consistent with that of other second-generation antipsychotics in that it has a higher affinity for the serotonin (5-HT) receptors compared with dopamine (D) receptors but with lower affinities for α-1 and histaminergic receptors. In addition, it serves as a presynaptic dopamine partial agonist, serotonin reuptake inhibitor, and an indirect modulator of glutamatergic systems. Based on the 4-week clinical trials, lumateperone was well tolerated. Most common treatment-emergent adverse events were headache, somnolence, and dizziness.

RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE

At this time, lumateperone had a statistically significant reduction in Positive and Negative Syndrome Scale when compared with placebo and was not significantly associated with the extrapyramidal symptoms (EPS) and metabolic adverse effects commonly seen with other antipsychotics.

CONCLUSIONS

Lumateperone has the potential to benefit individuals with schizophrenia who are intolerant to the EPSs or metabolic adverse effects of other antipsychotics. However, further head-to-head trials with commercially available antipsychotics are still required to assist in establishing its role in treatment.